🔎 Trials Near Me

Dachaigh › Leukemia myeloid geur › Minnesota

Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Minnesota

Tha 27 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann an Minnesota.

Bailtean ann an Minnesota

Teacsa sgrùdaidh oifigeil (Beurla)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • agus 8 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • University of Minnesota/Masonic Cancer Center, Minneapolis
A’ fastadhÌre 1
Suas gu aois 21 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07012044

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Riverwood Healthcare Center, Aitkin
  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Essentia Health - Baxter Clinic, Baxter
  • agus 48 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • agus 8 a bharrachd
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • agus 8 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • agus 9 a bharrachd
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • agus 8 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 3
6 Months – 21 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT04293562

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Mayo Clinic, Rochester
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Rochester MN-MAYOMN, Rochester
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 1/2
Suas gu aois 22 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Masonic Cancer Center, Minneapolis
A’ fastadhÌre 3
29 Days – 21 Years · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Minnesota, Minneapolis
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT07007312

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

  • Masonic Cancer Center, Minneapolis
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Iuch 2026 · NCT07008638

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

  • Masonic Cancer Center, Minneapolis
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Iuch 2026 · NCT06594445

Allo HSCT Using RIC and PTCy for Hematological Diseases

  • Masonic Cancer Center at University of Minnesota, Minneapolis
A’ fastadhÌre 2
Suas gu aois 75 · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT05805605

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

  • Masonic Cancer Center at University of Minnesota, Minneapolis
A’ fastadhÌre 2
Suas gu aois 60 · Gach gnè · Air ùrachadh 25 Ògmh 2026 · NCT03314974

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

  • Mark Juckett, MD, Minneapolis
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Cèit 2026 · NCT07591649

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

  • Masonic Cancer Center at University of Minnesota, Minneapolis
A’ fastadhÌre 2
Aoisean 2 gu 75 · Gach gnè · Air ùrachadh 16 Gibl 2026 · NCT07493538

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  • Mayo Clinic Comprehensive Cancer Center, Rochester
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gibl 2026 · NCT05732103

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

  • University of Minnesota/Masonic Cancer Center, Minneapolis
A’ fastadhSgrùdadh amharc
Suas gu aois 25 · Gach gnè · Air ùrachadh 8 Gibl 2026 · NCT05014165

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

  • University of Minnesota Masonic Cancer Center, Minneapolis
A’ fastadhÌre 2
Suas gu aois 60 · Gach gnè · Air ùrachadh 6 Gibl 2026 · NCT05735717

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

  • Mayo Clinic in Rochester, Rochester
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Gibl 2026 · NCT06279572

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Minnesota, Minneapolis
  • Mayo Clinic - Rochester, Rochester
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

  • Mayo Clinic, Rochester
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Gearr 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • Mayo Clinic, Rochester
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 25 Iuch 2025 · NCT05237258

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.